COMMUNIQUÉS West-GlobeNewswire

-
Beacon Health Selects R1 RCM for Expanded Revenue Cycle Services
23/04/2018 - 14:00 -
Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”
23/04/2018 - 14:00 -
Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations
23/04/2018 - 14:00 -
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
23/04/2018 - 14:00 -
Fulgent Genetics to Announce First Quarter 2018 Financial Results on Monday May 7, 2018
23/04/2018 - 14:00 -
Lotus Ventures Gets Confirmation of Readiness From Health Canada
23/04/2018 - 14:00 -
Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting
23/04/2018 - 14:00 -
San Antonio Endovascular & Heart Institute First to Deploy Biotricity’s New Bioflux Remote Monitoring Device
23/04/2018 - 14:00 -
Spectral Medical Completes $5.3 Million Financing
23/04/2018 - 14:00 -
Tabula Rasa Healthcare’s SinfoníaRx Publishes Annual Performance Report
23/04/2018 - 14:00 -
Precipio Completes a $3M Convertible Debt Facility
23/04/2018 - 13:37 -
Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS’ The Aesthetic Meeting
23/04/2018 - 13:30 -
Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
23/04/2018 - 13:30 -
Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections
23/04/2018 - 13:30 -
Misonix to Present at the 43rd Annual Deutsche Bank Health Care Conference on May 8
23/04/2018 - 13:30 -
Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018
23/04/2018 - 13:30 -
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
23/04/2018 - 13:05 -
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
23/04/2018 - 13:01 -
Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018
23/04/2018 - 13:00
Pages